| SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11bR)-3-ISOBUTYL-9,10-DIMETHOXY … |
2023-3-23 |
2023-5-16 |
|
| Crf1 receptor antagonist, and pharmaceutical formulations and solid forms … |
2023-3-06 |
2023-4-27 |
|
| Pharmaceutical formulations for treating endometriosis, uterine fibroids, … |
2023-2-13 |
2023-8-17 |
|
| Vmat2 inhibitors and methods of use |
2023-1-12 |
2023-5-25 |
|
| CRF1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA |
2022-12-07 |
2023-3-31 |
|
| Use of valbenazine for treating schizophrenia or schizoaffective disorder |
2022-11-28 |
2023-1-31 |
|
| CRF1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
2022-10-31 |
2022-12-08 |
|
| Valbenazine compositions |
2022-10-28 |
2023-5-04 |
|
| Methods for administration of certain vmat2 inhibitors |
2022-10-05 |
2022-11-22 |
|
| Methods for administration of certain vmat2 inhibitors |
2022-9-09 |
2022-11-04 |
|
| Methods of screening for vmat2 inhibitors |
2022-8-18 |
2023-2-23 |
|
| Muscarinic receptor 4 antagonists and methods of use |
2022-7-28 |
2023-2-02 |
|
| Valbenazine salts and polymorphs thereof |
2022-7-19 |
2022-9-29 |
|
| Valbenazine for use in the add-on treatment of schizophrenia |
2022-6-28 |
2023-1-05 |
|
| Valbenazine for use in the treatment of dyskinesia due to cerebral palsy |
2022-6-28 |
2023-1-05 |
|
| Processes for preparing a vmat2 inhibitor |
2022-4-28 |
2022-11-03 |
|
| Gpr52 modulators and methods of use |
2022-4-25 |
2022-11-03 |
|
| Processes for the synthesis of valbenazine |
2022-4-25 |
2022-11-03 |
|
| Methods for the combined administration of deutetrabenazine and a cyp2d6 … |
2022-4-14 |
2022-10-20 |
|
| Methods for the administration of certain vmat2 inhibitors |
2022-4-14 |
2022-10-20 |
|
| Processes for the synthesis of valbenazine |
2022-3-09 |
2022-5-01 |
|
| Treatment of cognitive impairment |
2022-3-01 |
2023-1-16 |
|
| Use of luvadaxistat for the treatment of cognitive impairment |
2022-2-28 |
2022-9-09 |
|
| Methods for the administration of certain vmat2 inhibitors to patients with … |
2022-2-17 |
2022-4-01 |
|
| Methods for administration of certain vmat2 inhibitors |
2022-1-24 |
2022-3-10 |
|
| Vmat2 inhibitors for treating neurological diseases or disorders |
2021-12-24 |
2022-2-18 |
|
| Methods for the administration of certain vmat2 inhibitors |
2021-11-08 |
2022-1-01 |
|
| Crf1 receptor antagonist, and pharmaceutical formulations and solid forms … |
2021-10-06 |
2022-1-04 |
|
| Methods for administration of certain vmat2 inhibitors |
2021-9-29 |
2021-12-23 |
|
| Vmat2 inhibitor for treatment of hyperkinetic movement disorders |
2021-9-22 |
2021-12-16 |
|
| Crf receptor antagonists and methods of use |
2021-8-25 |
2022-3-03 |
|
| N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide … |
2021-4-26 |
2021-11-04 |
|
| Gpr52 modulators and methods of use |
2021-4-21 |
2021-10-28 |
|
| Methods for the administration of comt inhibitors |
2021-4-01 |
2021-7-22 |
|
| Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 … |
2021-3-02 |
2021-5-27 |
|
| Muscarinic receptor 4 antagonists and methods of use |
2021-2-03 |
2022-11-18 |
|
| Gonadotropin-releasing hormone receptor antagonists and methods relating … |
2020-12-18 |
2023-8-01 |
2023-8-01 |
| Vmat2 inhibitor compounds, compositions, and methods relating thereto |
2020-12-04 |
2021-8-02 |
|
| MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE |
2020-12-03 |
2022-3-09 |
|
| Muscarinic receptor 4 antagonists and methods of use |
2020-12-03 |
2021-6-10 |
|
| CRF RECEPTOR ANTAGONISTS AND METHODS OF USE |
2020-12-01 |
2022-3-09 |
|
| High dosage valbenazine formulation and compositions, methods, and kits related … |
2020-10-19 |
2021-6-08 |
2021-6-08 |
| CRF receptor antagonists and methods of use |
2020-9-25 |
2022-5-13 |
|
| Substituted triazoles and methods relating thereto |
2020-6-04 |
2021-6-01 |
2021-6-01 |
| Methods for the administration of certain VMAT2 inhibitors |
2020-5-08 |
2021-5-04 |
2021-5-04 |
| [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a] … |
2020-1-22 |
2020-8-20 |
|
| Processes for the preparation of uracil derivatives |
2020-1-10 |
2020-8-13 |
|
| Processes for preparing a vmat2 inhibitor |
2019-10-23 |
2020-4-30 |
|
| Vmat2 inhibitor compounds, compositions and methods relating thereto |
2019-10-18 |
2019-10-31 |
|
| Methods for the administration of comt inhibitors |
2019-10-04 |
2020-4-09 |
|
| HIGH DOSE VALBENAZINE FORMULATION AND COMPOSITIONS, RELATED METHODS AND … |
2018-9-18 |
2019-12-18 |
|
| Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, … |
2018-8-20 |
2019-2-21 |
|
| Novel Bioavailability Enhancement Composition |
2018-7-11 |
2019-1-17 |
|
| Use of valbenazine for treating levodopa-induced dyskinesia |
2018-4-25 |
2018-11-01 |
|
| VMAT2 INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS RELATED TO THE SAME |
2018-4-17 |
2019-7-17 |
|
| Valbenazine salts and polymorphs thereof |
2018-4-16 |
2019-10-16 |
|
| Dosing regimen for valbenazine |
2018-3-05 |
2018-9-13 |
|
| Methods of administering certain VMAT2 inhibitors |
2017-10-10 |
2023-9-08 |
|
| Methods for the administration of certain VMAT2 inhibitors |
2017-10-10 |
2023-6-29 |
2023-6-29 |
| Pharmaceutical formulations for treating endometriosis and uterine fibroids |
2017-9-01 |
2019-2-18 |
|
| Muscarinic receptor 4 antagonists and methods of using same |
2016-11-04 |
2022-2-21 |
|
| Tamper-resistant pharmaceutical dosage forms and process for making same |
2016-3-02 |
2018-7-03 |
2018-7-03 |
| Utilisation de luvadaxistat pour le traitement d'une deficience cognitive |
2022-2-28 |
2022-9-09 |
|
| 施用某些vmat2抑制剂的方法 |
2017-10-10 |
2023-9-08 |
|